1,2-dimethylhydrazine multiple interactions ISO RGD:1317144 6480464 Folic Acid inhibits the reaction [1, 2-Dimethylhydrazine results in increased expression of ELK3 mRNA] CTD PMID:22206623 1,2-dimethylhydrazine increases expression ISO RGD:1317144 6480464 1, 2-Dimethylhydrazine results in increased expression of ELK3 mRNA CTD PMID:22206623 17alpha-ethynylestradiol increases expression ISO RGD:1317144 6480464 Ethinyl Estradiol results in increased expression of ELK3 mRNA CTD PMID:17942748 17alpha-ethynylestradiol affects expression ISO RGD:1317144 6480464 Ethinyl Estradiol affects the expression of ELK3 mRNA CTD PMID:17555576 17alpha-ethynylestradiol multiple interactions ISO RGD:1317144 6480464 [Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of ELK3 mRNA CTD PMID:17942748 17beta-estradiol multiple interactions ISO RGD:1317143 6480464 [Estradiol co-treated with Tetrachlorodibenzodioxin] results in increased expression of ELK3 mRNA, [Estradiol co-treated with TGFB1 protein] results in increased expression of ELK3 mRNA CTD PMID:19619570 , PMID:30165855 17beta-estradiol increases expression ISO RGD:1317143 6480464 Estradiol results in increased expression of ELK3 mRNA CTD PMID:19619570 2,3,7,8-tetrachlorodibenzodioxine increases expression ISO RGD:1317144 6480464 Tetrachlorodibenzodioxin results in increased expression of ELK3 mRNA CTD PMID:24058054 2,3,7,8-tetrachlorodibenzodioxine decreases expression EXP 6480464 Tetrachlorodibenzodioxin results in decreased expression of ELK3 mRNA CTD PMID:33387578 2,3,7,8-tetrachlorodibenzodioxine affects expression EXP 6480464 Tetrachlorodibenzodioxin affects the expression of ELK3 mRNA CTD PMID:34747641 2,3,7,8-tetrachlorodibenzodioxine affects expression ISO RGD:1317144 6480464 Tetrachlorodibenzodioxin affects the expression of ELK3 mRNA CTD PMID:21570461 2,3,7,8-tetrachlorodibenzodioxine multiple interactions ISO RGD:1317144 6480464 [Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of ELK3 mRNA CTD PMID:17942748 2,3,7,8-tetrachlorodibenzodioxine increases expression ISO RGD:1317143 6480464 Tetrachlorodibenzodioxin results in increased expression of ELK3 mRNA CTD PMID:19619570 2,3,7,8-tetrachlorodibenzodioxine multiple interactions ISO RGD:1317143 6480464 [Estradiol co-treated with Tetrachlorodibenzodioxin] results in increased expression of ELK3 mRNA CTD PMID:19619570 2,4-dinitrotoluene affects expression EXP 6480464 2, 4-dinitrotoluene affects the expression of ELK3 mRNA CTD PMID:21346803 3,4-methylenedioxymethamphetamine increases expression ISO RGD:1317144 6480464 N-Methyl-3, 4-methylenedioxyamphetamine results in increased expression of ELK3 mRNA CTD PMID:20188158 4,4'-sulfonyldiphenol increases expression ISO RGD:1317144 6480464 bis(4-hydroxyphenyl)sulfone results in increased expression of ELK3 mRNA CTD PMID:30951980 4,4'-sulfonyldiphenol affects methylation ISO RGD:1317144 6480464 bis(4-hydroxyphenyl)sulfone affects the methylation of ELK3 gene CTD PMID:31683443 4-hydroxyphenyl retinamide increases expression ISO RGD:1317144 6480464 Fenretinide results in increased expression of ELK3 mRNA CTD PMID:28973697 acetamide increases expression EXP 6480464 acetamide results in increased expression of ELK3 mRNA CTD PMID:31881176 aflatoxin B1 increases expression ISO RGD:1317143 6480464 Aflatoxin B1 results in increased expression of ELK3 mRNA CTD PMID:22100608 aldehydo-D-glucose increases expression ISO RGD:1317144 6480464 Glucose results in increased expression of ELK3 mRNA CTD PMID:17178593 all-trans-retinoic acid increases expression ISO RGD:1317143 6480464 Tretinoin results in increased expression of ELK3 mRNA CTD PMID:21934132 more ... arsenite(3-) multiple interactions ISO RGD:1317143 6480464 arsenite promotes the reaction [G3BP1 protein binds to ELK3 mRNA] CTD PMID:32406909 benzo[a]pyrene decreases expression ISO RGD:1317143 6480464 Benzo(a)pyrene results in decreased expression of ELK3 mRNA CTD PMID:20064835 benzo[a]pyrene increases expression ISO RGD:1317143 6480464 Benzo(a)pyrene results in increased expression of ELK3 mRNA CTD PMID:32234424 benzo[a]pyrene decreases methylation ISO RGD:1317143 6480464 Benzo(a)pyrene results in decreased methylation of ELK3 promoter CTD PMID:27901495 benzo[a]pyrene increases expression ISO RGD:1317144 6480464 Benzo(a)pyrene results in increased expression of ELK3 mRNA CTD PMID:32417428 benzo[a]pyrene affects methylation ISO RGD:1317143 6480464 Benzo(a)pyrene affects the methylation of ELK3 5' UTR CTD PMID:27901495 benzo[a]pyrene decreases expression ISO RGD:1317144 6480464 Benzo(a)pyrene results in decreased expression of ELK3 mRNA CTD PMID:19770486 more ... bisphenol A decreases expression EXP 6480464 bisphenol A results in decreased expression of ELK3 mRNA CTD PMID:25181051 more ... bisphenol A increases expression ISO RGD:1317144 6480464 bisphenol A results in increased expression of ELK3 mRNA CTD PMID:30951980 bisphenol F increases expression ISO RGD:1317144 6480464 bisphenol F results in increased expression of ELK3 mRNA CTD PMID:30951980 carbon nanotube decreases expression ISO RGD:1317144 6480464 Nanotubes more ... CTD PMID:25554681 , PMID:25620056 cisplatin decreases expression EXP 6480464 Cisplatin results in decreased expression of ELK3 mRNA CTD PMID:22023808 cobalt dichloride decreases expression ISO RGD:1317143 6480464 cobaltous chloride results in decreased expression of ELK3 mRNA CTD PMID:19320972 copper(II) sulfate increases expression ISO RGD:1317143 6480464 Copper Sulfate results in increased expression of ELK3 mRNA CTD PMID:19549813 coumestrol decreases expression ISO RGD:1317143 6480464 Coumestrol results in decreased expression of ELK3 mRNA CTD PMID:19167446 Cuprizon increases expression EXP 6480464 Cuprizone results in increased expression of ELK3 mRNA CTD PMID:26577399 D-glucose increases expression ISO RGD:1317144 6480464 Glucose results in increased expression of ELK3 mRNA CTD PMID:17178593 diazinon increases methylation ISO RGD:1317143 6480464 Diazinon results in increased methylation of ELK3 gene CTD PMID:22964155 diuron increases expression EXP 6480464 Diuron results in increased expression of ELK3 mRNA CTD PMID:21551480 dorsomorphin multiple interactions ISO RGD:1317143 6480464 [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... CTD PMID:27188386 doxorubicin decreases expression ISO RGD:1317143 6480464 Doxorubicin results in decreased expression of ELK3 mRNA CTD PMID:29803840 endosulfan decreases expression EXP 6480464 Endosulfan results in decreased expression of ELK3 mRNA CTD PMID:29391264 entinostat increases expression ISO RGD:1317143 6480464 entinostat results in increased expression of ELK3 mRNA CTD PMID:26272509 entinostat multiple interactions ISO RGD:1317143 6480464 [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELK3 mRNA CTD PMID:27188386 ethanol increases expression ISO RGD:1317144 6480464 Ethanol results in increased expression of ELK3 mRNA CTD PMID:30319688 fenamidone increases expression ISO RGD:1317144 6480464 fenamidone results in increased expression of ELK3 mRNA CTD PMID:27029645 folic acid multiple interactions ISO RGD:1317144 6480464 Folic Acid inhibits the reaction [1, 2-Dimethylhydrazine results in increased expression of ELK3 mRNA] CTD PMID:22206623 formaldehyde increases expression ISO RGD:1317143 6480464 Formaldehyde results in increased expression of ELK3 mRNA CTD PMID:23649840 gentamycin increases expression EXP 6480464 Gentamicins results in increased expression of ELK3 mRNA CTD PMID:22061828 gentamycin decreases expression EXP 6480464 Gentamicins results in decreased expression of ELK3 mRNA CTD PMID:33387578 glucose increases expression ISO RGD:1317144 6480464 Glucose results in increased expression of ELK3 mRNA CTD PMID:17178593 hydralazine multiple interactions ISO RGD:1317143 6480464 [Hydralazine co-treated with Valproic Acid] results in increased expression of ELK3 mRNA CTD PMID:17183730 indometacin decreases expression EXP 6480464 Indomethacin results in decreased expression of ELK3 mRNA CTD PMID:25972201 lipopolysaccharide decreases expression ISO RGD:1317144 6480464 Lipopolysaccharides results in decreased expression of ELK3 mRNA CTD PMID:12057914 lipopolysaccharide multiple interactions ISO RGD:1317143 6480464 [S-(1, 2-dichlorovinyl)cysteine co-treated with Lipopolysaccharides] results in decreased expression of ELK3 mRNA CTD PMID:35811015 manganese(II) chloride increases expression ISO RGD:1317144 6480464 manganese chloride results in increased expression of ELK3 mRNA CTD PMID:17467022 mercury dibromide increases expression ISO RGD:1317143 6480464 mercuric bromide results in increased expression of ELK3 mRNA CTD PMID:26272509 mercury dibromide multiple interactions ISO RGD:1317143 6480464 [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELK3 mRNA CTD PMID:27188386 methylmercury chloride increases expression ISO RGD:1317143 6480464 methylmercuric chloride results in increased expression of ELK3 mRNA CTD PMID:23179753 more ... methylmercury chloride multiple interactions ISO RGD:1317143 6480464 [NOG protein co-treated with methylmercuric chloride co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELK3 mRNA CTD PMID:27188386 methylparaben decreases expression ISO RGD:1317143 6480464 methylparaben results in decreased expression of ELK3 mRNA CTD PMID:31745603 mitomycin C affects response to substance ISO RGD:1317143 6480464 ELK3 protein affects the susceptibility to Mitomycin CTD PMID:16217747 N,N-diethyl-m-toluamide multiple interactions EXP 6480464 [Permethrin co-treated with DEET] results in decreased methylation of ELK3 gene CTD PMID:33148267 N-methyl-N'-nitro-N-nitrosoguanidine increases expression ISO RGD:1317143 6480464 Methylnitronitrosoguanidine results in increased expression of ELK3 mRNA CTD PMID:12634122 oxaliplatin multiple interactions EXP 6480464 [oxaliplatin co-treated with Topotecan] results in decreased expression of ELK3 mRNA CTD PMID:25729387 panobinostat increases expression ISO RGD:1317143 6480464 panobinostat results in increased expression of ELK3 mRNA CTD PMID:26272509 panobinostat multiple interactions ISO RGD:1317143 6480464 [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELK3 mRNA CTD PMID:27188386 paracetamol affects expression ISO RGD:1317144 6480464 Acetaminophen affects the expression of ELK3 mRNA CTD PMID:17562736 paracetamol decreases expression EXP 6480464 Acetaminophen results in decreased expression of ELK3 mRNA CTD PMID:33387578 paracetamol decreases expression ISO RGD:1317143 6480464 Acetaminophen results in decreased expression of ELK3 mRNA CTD PMID:21420995 permethrin multiple interactions EXP 6480464 [Permethrin co-treated with DEET] results in decreased methylation of ELK3 gene CTD PMID:33148267 phenobarbital increases expression ISO RGD:1317144 6480464 Phenobarbital results in increased expression of ELK3 mRNA CTD PMID:19270015 phenylmercury acetate increases expression ISO RGD:1317143 6480464 Phenylmercuric Acetate results in increased expression of ELK3 mRNA CTD PMID:26272509 phenylmercury acetate multiple interactions ISO RGD:1317143 6480464 [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELK3 mRNA CTD PMID:27188386 phosgene affects expression ISO RGD:1317144 6480464 Phosgene affects the expression of ELK3 mRNA CTD PMID:16300373 pirinixic acid decreases expression ISO RGD:1317144 6480464 pirinixic acid results in decreased expression of ELK3 mRNA CTD PMID:18445702 rotenone increases expression ISO RGD:1317143 6480464 Rotenone results in increased expression of ELK3 mRNA CTD PMID:29955902 rotenone increases expression ISO RGD:1317144 6480464 Rotenone results in increased expression of ELK3 mRNA CTD PMID:32937126 S-(1,2-dichlorovinyl)-L-cysteine multiple interactions ISO RGD:1317143 6480464 [S-(1, 2-dichlorovinyl)cysteine co-treated with Lipopolysaccharides] results in decreased expression of ELK3 mRNA CTD PMID:35811015 SB 431542 multiple interactions ISO RGD:1317143 6480464 [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... CTD PMID:27188386 silver atom decreases expression ISO RGD:1317144 6480464 Silver results in decreased expression of ELK3 mRNA CTD PMID:27131904 silver atom increases expression ISO RGD:1317143 6480464 Silver results in increased expression of ELK3 mRNA CTD PMID:26014281 silver(0) decreases expression ISO RGD:1317144 6480464 Silver results in decreased expression of ELK3 mRNA CTD PMID:27131904 silver(0) increases expression ISO RGD:1317143 6480464 Silver results in increased expression of ELK3 mRNA CTD PMID:26014281 sodium arsenite increases expression ISO RGD:1317143 6480464 sodium arsenite results in increased expression of ELK3 mRNA CTD PMID:12760830 , PMID:20886546 sodium arsenite affects methylation ISO RGD:1317143 6480464 sodium arsenite affects the methylation of ELK3 gene CTD PMID:28589171 Soman increases expression EXP 6480464 Soman results in increased expression of ELK3 mRNA CTD PMID:19281266 sunitinib decreases expression ISO RGD:1317143 6480464 Sunitinib results in decreased expression of ELK3 mRNA CTD PMID:31533062 thioacetamide increases expression EXP 6480464 Thioacetamide results in increased expression of ELK3 mRNA CTD PMID:34492290 topotecan multiple interactions EXP 6480464 [oxaliplatin co-treated with Topotecan] results in decreased expression of ELK3 mRNA CTD PMID:25729387 topotecan decreases expression EXP 6480464 Topotecan results in decreased expression of ELK3 mRNA CTD PMID:25729387 trichostatin A increases expression ISO RGD:1317143 6480464 trichostatin A results in increased expression of ELK3 mRNA CTD PMID:24935251 , PMID:26272509 trichostatin A multiple interactions ISO RGD:1317143 6480464 [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELK3 mRNA CTD PMID:27188386 tris(2-butoxyethyl) phosphate affects expression ISO RGD:1317143 6480464 tris(2-butoxyethyl) phosphate affects the expression of ELK3 mRNA CTD PMID:29024780 tungsten decreases expression ISO RGD:1317144 6480464 Tungsten results in decreased expression of ELK3 mRNA CTD PMID:30912803 valproic acid affects expression ISO RGD:1317144 6480464 Valproic Acid affects the expression of ELK3 mRNA CTD PMID:17963808 valproic acid increases expression ISO RGD:1317143 6480464 Valproic Acid results in increased expression of ELK3 mRNA CTD PMID:23179753 more ... valproic acid multiple interactions ISO RGD:1317143 6480464 [Hydralazine co-treated with Valproic Acid] results in increased expression of ELK3 mRNA more ... CTD PMID:17183730 , PMID:27188386 vinclozolin affects expression EXP 6480464 vinclozolin affects the expression of ELK3 mRNA CTD PMID:19015723 vinclozolin increases expression EXP 6480464 vinclozolin results in increased expression of ELK3 mRNA CTD PMID:23034163 vincristine increases expression ISO RGD:1317143 6480464 Vincristine results in increased expression of ELK3 mRNA CTD PMID:23649840 vorinostat multiple interactions ISO RGD:1317143 6480464 [NOG protein co-treated with Vorinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELK3 mRNA CTD PMID:27188386 vorinostat increases expression ISO RGD:1317143 6480464 vorinostat results in increased expression of ELK3 mRNA CTD PMID:26272509